Let’s start up with the current stock price of Vascular Biogenics Ltd. (VBLT), which is $0.17 to be very precise. The Stock rose vividly during the last session to $0.1878 after opening rate of $0.1828 while the lowest price it went was recorded $0.1623 before closing at $0.19.Recently in News on September 1, 2022, VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency. VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 31, 2022, notifying VBL that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. You can read further details here
Vascular Biogenics Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.2000 on 07/11/22, with the lowest value was $0.1623 for the same time period, recorded on 09/20/22.
Vascular Biogenics Ltd. (VBLT) full year performance was -92.54%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Vascular Biogenics Ltd. shares are logging -93.43% during the 52-week period from high price, and -7.89% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.18 and $2.54.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2505250 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Vascular Biogenics Ltd. (VBLT) recorded performance in the market was -91.52%, having the revenues showcasing -87.99% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 12.35M, as it employees total of 41 workers.
Analysts verdict on Vascular Biogenics Ltd. (VBLT)
During the last month, 1 analysts gave the Vascular Biogenics Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.0102, with a change in the price was noted -1.40. In a similar fashion, Vascular Biogenics Ltd. posted a movement of -89.36% for the period of last 100 days, recording 2,605,140 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VBLT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Vascular Biogenics Ltd. (VBLT): Technical Analysis
Raw Stochastic average of Vascular Biogenics Ltd. in the period of last 50 days is set at 0.23%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 5.91%. In the last 20 days, the company’s Stochastic %K was 8.11% and its Stochastic %D was recorded 15.80%.
Let’s take a glance in the erstwhile performances of Vascular Biogenics Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -91.52%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -88.79%, alongside a downfall of -92.54% for the period of the last 12 months. The shares increased approximately by -15.27% in the 7-day charts and went up by -26.88% in the period of the last 30 days. Common stock shares were lifted by -87.99% during last recorded quarter.